Revive Therapeutics (CVE:RVV) Sets New 1-Year Low at $0.08

Revive Therapeutics Ltd (CVE:RVV)’s stock price hit a new 52-week low on Thursday . The stock traded as low as C$0.08 and last traded at C$0.09, with a volume of 208716 shares traded. The stock had previously closed at C$0.09.

The stock has a market capitalization of $6.52 million and a PE ratio of -3.41. The business has a fifty day moving average price of C$0.10.

About Revive Therapeutics (CVE:RVV)

Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial.

Recommended Story: How is diluted EPS different from basic EPS?

Receive News & Ratings for Revive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.